CoChat
Sign Up
Cited by 29Mosquito-borne diseases and controlVirus-based gene therapy researchSARS-CoV-2 and COVID-19 Research

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus

Open access
Ku, Min Wen, Anna, François, Souque, Philippe, Petres, Stéphane, Prot, Matthieu, Simon-Loriere, Etienne, Charneau, Pierre, Bourgine, Maryline·2020·Molecular Therapy
DOI 10.1016/j.ymthe.2020.05.016PMC PMC7403329
Open this paper in CoChat — free accountOpen PDF

Abstract

Zika virus, a member of the Flaviviridae family, is primarily transmitted by infected Aedes species mosquitoes. In 2016, Zika infection emerged as a global health emergency for its explosive spread and the remarkable neurological defects in the developing fetus. Development of a safe and effective Zika vaccine remains a high priority owing to the risk of re-emergence and limited understanding of Zika virus epidemiology. We engineered a non-integrating lentiviralvector(NILV)-based Zika vaccine encoding the consensus pre-membrane and envelope glycoprotein of circulating Zika virus strains. We further evaluated the immunogenicity and protective efficacy of this vaccine in both immunocompromised and immunocompetent mouse models. A single immunization in both mouse models elicited a robust neutralizing antibody titer and afforded full protection against Zika challenge as early as 7 days post-immunization. This NILV-based vaccine also induced a long-lasting immunity when immunized mice were challenged 6 months after immunization. Altogether, our NILV Zika vaccine provides a rapid yet durable protection through a single dose of immunization without extra adjuvant formulation. Our data suggest a promising Zika vaccine candidate for an emergency situation, and demonstrate the capacity of lentiviral vector as an efficient vaccine delivery platform.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2020.05.016

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Vaccinia virus, Zika virus, and human cytomegalovirus have been investigated in pre-clinical studies to test immune responses.

    “Vaccinia virus [81], Zika virus [82], and human cytomegalovirus [83] have also been investigated in pre-clinical studies to test their immune responses.”

    From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [82]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. Petersen, 2016, Zika virus, N. Engl. J. Med., 374, 1552, 10.1056/NEJMra1602113 · DOI
  2. Rasmussen, 2016, Zika virus and birth defects—reviewing the evidence for causality, N. Engl. J. Med., 374, 1981, 10.1056/NEJMsr1604338 · DOI
  3. Moreira, 2017, Sexually acquired Zika virus: a systematic review, Clin. Microbiol. Infect., 23, 296, 10.1016/j.cmi.2016.12.027 · DOI
  4. van der Eijk, 2016, Miscarriage associated with Zika virus infection, N. Engl. J. Med., 375, 1002, 10.1056/NEJMc1605898 · DOI
  5. Muñoz, 2017, Neurological Implications of Zika Virus Infection in Adults, J. Infect. Dis., 216, S897, 10.1093/infdis/jix511 · DOI
  6. Dowd, 2016, Rapid development of a DNA vaccine for Zika virus, Science, 354, 237, 10.1126/science.aai9137 · DOI
  7. Larocca, 2016, Vaccine protection against Zika virus from Brazil, Nature, 536, 474, 10.1038/nature18952 · DOI
  8. Zou, 2018, A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity, EBioMedicine, 36, 92, 10.1016/j.ebiom.2018.08.056 · DOI
  9. Richner, 2017, Modified mRNA vaccines protect against Zika virus infection, Cell, 168, 1114, 10.1016/j.cell.2017.02.017 · DOI · Paper page
  10. Dai, 2009, HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells, Proc. Natl. Acad. Sci. USA, 106, 20382, 10.1073/pnas.0911742106 · DOI
  11. Esslinger, 2003, In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses, J. Clin. Invest., 111, 1673, 10.1172/JCI200317098 · DOI
  12. Furmanov, 2010, The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors, J. Immunol., 184, 4889, 10.4049/jimmunol.0903062 · DOI
  13. Ciré, 2014, Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo, PLoS ONE, 9, e101644, 10.1371/journal.pone.0101644 · DOI
  14. Kim, 2017, Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation, Sci. Immunol., 2, 10.1126/sciimmunol.aal1329 · DOI
  15. Follenzi, 2007, Immune responses to lentiviral vectors, Curr. Gene Ther., 7, 306, 10.2174/156652307782151515 · DOI · Paper page
  16. Heinz, 1986, Epitope mapping of flavivirus glycoproteins, Adv. Virus Res., 31, 103, 10.1016/S0065-3527(08)60263-8 · DOI
  17. de Wispelaere, 2015, A lentiviral vector expressing Japanese encephalitis virus-like particles elicits broad neutralizing antibody response in pigs, PLoS Negl. Trop. Dis., 9, e0004081, 10.1371/journal.pntd.0004081 · DOI
  18. Wang, 2001, Immunization of mice against West Nile virus with recombinant envelope protein, J. Immunol., 167, 5273, 10.4049/jimmunol.167.9.5273 · DOI
  19. Davis, 2001, West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays, J. Virol., 75, 4040, 10.1128/JVI.75.9.4040-4047.2001 · DOI
  20. Frumence, 2019, A chimeric Zika virus between viral strains MR766 and BeH819015 highlights a role for E-glycan loop in antibody-mediated virus neutralization, Vaccines (Basel), 7, 55, 10.3390/vaccines7020055 · DOI
  21. Philippe, 2006, Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo, Proc. Natl. Acad. Sci. USA, 103, 17684, 10.1073/pnas.0606197103 · DOI · Paper page
  22. Coutant, 2012, A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria, PLoS ONE, 7, e48644, 10.1371/journal.pone.0048644 · DOI · Paper page
  23. Lazear, 2016, A mouse model of Zika virus pathogenesis, Cell Host Microbe, 19, 720, 10.1016/j.chom.2016.03.010 · DOI · Paper page
  24. Dowall, 2016, A susceptible mouse model for Zika virus infection. PLoS Negl. Trop, Dis., 10, e0004658
  25. Duggal, 2017, Frequent Zika virus sexual transmission and prolonged viral RNA shedding in an immunodeficient mouse model, Cell Rep., 18, 1751, 10.1016/j.celrep.2017.01.056 · DOI
  26. Atkinson, 2017, Presence and persistence of Zika virus RNA in semen, United Kingdom, 2016, Emerg. Infect. Dis., 23, 611, 10.3201/eid2304.161692 · DOI
  27. Emanuel, 2018, A VSV-based Zika virus vaccine protects mice from lethal challenge, Sci. Rep., 8, 11043, 10.1038/s41598-018-29401-x · DOI
  28. Abbink, 2017, Durability and correlates of vaccine protection against Zika virus in rhesus monkeys, Sci. Transl. Med., 9, eaao4163, 10.1126/scitranslmed.aao4163 · DOI
  29. Cox, 2018, Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge, PLoS ONE, 13, e0202820, 10.1371/journal.pone.0202820 · DOI
  30. Hassan, 2019, A gorilla adenovirus-based vaccine against Zika virus induces durable immunity and confers protection in pregnancy, Cell Rep., 28, 2634, 10.1016/j.celrep.2019.08.005 · DOI
  31. Eisen, 1964, Variations in affinities of antibodies during the immune response, Biochemistry, 3, 996, 10.1021/bi00895a027 · DOI
  32. Bernstein, 2005, Glycoprotein D adjuvant herpes simplex virus vaccine, Expert Rev. Vaccines, 4, 615, 10.1586/14760584.4.5.615 · DOI
  33. Corey, 1999, Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials, JAMA, 282, 331, 10.1001/jama.282.4.331 · DOI
  34. Stanberry, 2002, Glycoprotein-D-adjuvant vaccine to prevent genital herpes, N. Engl. J. Med., 347, 1652, 10.1056/NEJMoa011915 · DOI
  35. Klein, 2010, The Xs and Y of immune responses to viral vaccines, Lancet Infect. Dis., 10, 338, 10.1016/S1473-3099(10)70049-9 · DOI
  36. Živković, 2015, Sexual diergism in antibody response to whole virus trivalent inactivated influenza vaccine in outbred mice, Vaccine, 33, 5546, 10.1016/j.vaccine.2015.09.006 · DOI
  37. Fink, 2018, Biological sex affects vaccine efficacy and protection against influenza in mice, Proc. Natl. Acad. Sci. USA, 115, 12477, 10.1073/pnas.1805268115 · DOI
  38. Stassen, 2018, Zika virus in the male reproductive tract, Viruses, 10, 198, 10.3390/v10040198 · DOI
  39. Arsuaga, 2016, Probable sexual transmission of Zika virus from a vasectomised man, Lancet Infect. Dis., 16, 1107, 10.1016/S1473-3099(16)30320-6 · DOI
  40. Stettler, 2016, Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection, Science, 353, 823, 10.1126/science.aaf8505 · DOI
  41. Barba-Spaeth, 2016, Structural basis of potent Zika-dengue virus antibody cross-neutralization, Nature, 536, 48, 10.1038/nature18938 · DOI
  42. Beltramello, 2010, The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity, Cell Host Microbe, 8, 271, 10.1016/j.chom.2010.08.007 · DOI
  43. Dejnirattisai, 2010, Cross-reacting antibodies enhance dengue virus infection in humans, Science, 328, 745, 10.1126/science.1185181 · DOI
  44. Langerak, 2019, The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis, PLoS Pathog., 15, e1007640, 10.1371/journal.ppat.1007640 · DOI
  45. Martín-Acebes, 2018, Antibody-dependent enhancement and Zika: real threat or phantom menace?, Front. Cell. Infect. Microbiol., 8, 44, 10.3389/fcimb.2018.00044 · DOI
  46. Larocca, 2019, Adenovirus vector-based vaccines confer maternal-fetal protection against Zika virus challenge in pregnant IFN-αβR−/− mice, Cell Host Microbe, 26, 591, 10.1016/j.chom.2019.10.001 · DOI
  47. Benson, 2007, GenBank, Nucleic Acids Res., 35, D21, 10.1093/nar/gkl986 · DOI
  48. Corpet, 1988, Multiple sequence alignment with hierarchical clustering, Nucleic Acids Res., 16, 10881, 10.1093/nar/16.22.10881 · DOI
  49. Zennou, 2000, HIV-1 genome nuclear import is mediated by a central DNA flap, Cell, 101, 173, 10.1016/S0092-8674(00)80828-4 · DOI
  50. Iglesias, 2006, A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus, J. Gene Med., 8, 265, 10.1002/jgm.837 · DOI
  51. Faye, 2013, Quantitative real-time PCR detection of Zika virus and evaluation with field-caught mosquitoes, Virol. J., 10, 311, 10.1186/1743-422X-10-311 · DOI
  52. Lanciotti, 2008, Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007, Emerg. Infect. Dis., 14, 1232, 10.3201/eid1408.080287 · DOI
  53. Reed, 1938, A simple method of estimating fifty percent endpoints, Am. J. Epidemiol., 27, 493, 10.1093/oxfordjournals.aje.a118408 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ku, M. W., Anna, F., Souque, P., Petres, S., Prot, M., Simon-Loriere, E., Charneau, P., & Bourgine, M.
Affiliations
Institut Pasteur (FR)
Corresponding author
  • Charneau, Pierre
  • Bourgine, Maryline
ORCID
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2020-08
Volume
28
Issue
8
Pages
1772-1782
ISSN
1525-0016 (ISSN-L)
DOI
10.1016/j.ymthe.2020.05.016
PMC
PMC7403329
OpenAlex
W3027753781
Cited by
29
References
2
Citations by year
2025: 5 · 2024: 1 · 2023: 7 · 2022: 6 · 2021: 6 · 2020: 4
FWCI
4.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc-nd)
Funders
  • Pasteur-Paris University
  • Institut Carnot Pasteur Microbes & Santé
  • Marie Sklodowska-Curie (665807)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Mosquito-borne diseases and control
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
Zika virus, vaccines, single-dose vaccination, neutralizing antibodies, long-term immunity, immunodeficient mice, immunocompetent mice, Aedes mosquito transmission, flavivirus
MeSH terms
Zika Virus Infection, Zika Virus, Immunogenicity, Vaccine, Animals, Antibodies, Viral, Cross Reactions, Disease Models, Animal, Genetic Vectors, Immunization, Viral Envelope Proteins, Viral Vaccines, Lentivirus, Vaccines, DNA, Mice, Host-Pathogen Interactions, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review